Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Revance’s Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc’s blockbuster Botox passed a late-stage study, putting drug developer Revance Therapeutics Inc. on course to file for U.S. marketing approval in 2019.

Read More »

GSK buying cancer firm Tesaro for $5.1 billion

GlaxoSmithKline agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, a costly investment to rebuild the pharma business by new Chief Executive Emma Walmsley that unnerved investors.

Read More »

FDA approves Catalyst Pharma’s rare disease drug

The U.S. Food and Drug Administration approved Catalyst Pharmaceuticals Inc.’s drug Firdapse to treat a rare autoimmune disease.

Read More »

Humana cuts 2019 forecast for Medicare prescription drug plans

Health insurer Humana Inc. said on Wednesday that enrollment for its 2019 Medicare prescription drug plans dropped as customers opted for lower priced options from rivals.

Read More »

Health stocks up on U.S. vote, insurers hit records

Healthcare stocks rallied with U.S. health insurers reaching record highs as results of the 2018 mid-term elections were seen reducing the likelihood of action to cut medical costs and programs in the world’s biggest and most profitable market.

Read More »

Lilly’s Trulicity reduces heart risks in clinical study

Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.

Read More »

Bayer, Orion drug delays spread of prostate cancer

German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.

Read More »

Biogen, UCB’s Lupus Treatment Fails Phase II Study

Cambridge, Mass.-based Biogen and Brussels, Belgium-based UCB’s Phase IIb trial of dapirolizumab pegol in lupus failed to hit the primary endpoint, however, the study did show some efficacy and met other secondary endpoints.

Read More »

Shire’s Takhzyro for rare swelling disorder wins European panel green light

An EMA panel recommended approving a potential blockbuster drug from Shire Plc to treat a rare hereditary disease.

Read More »

Proteostasis Therapeutics’ Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance

Boston-based Proteostasis Therapeutics announced positive preliminary data from the ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis. Despite being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading hands.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom